Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)
Close on Nov 17, 2026Market cap $1.56BP/E –Yield –
Sarepta Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Sarepta Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$143.25M. For fiscal 2025 it was -$699.78M, down 420.9% from the year before. The highest annual figure on record is $218.08M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$699.78M | -420.9% |
| FY2024 | Dec 31, 2024 | $218.08M | – |
| FY2023 | Dec 31, 2023 | -$267.82M | – |
| FY2022 | Dec 31, 2022 | -$536.20M | – |
| FY2021 | Dec 31, 2021 | -$459.71M | – |
| FY2020 | Dec 31, 2020 | -$564.16M | – |
| FY2019 | Dec 31, 2019 | -$705.56M | – |
| FY2018 | Dec 31, 2018 | -$343.63M | – |
| FY2017 | Dec 31, 2017 | -$171.64M | – |
| FY2016 | Dec 31, 2016 | -$266.73M | – |
| FY2015 | Dec 31, 2015 | -$220.18M | – |
| FY2014 | Dec 31, 2014 | -$133.79M | – |
| FY2013 | Dec 31, 2013 | -$90.28M | – |
| FY2012 | Dec 31, 2012 | -$29.70M | – |
| FY2011 | Dec 31, 2011 | -$35.93M | – |
| FY2010 | Dec 31, 2010 | -$20.93M | – |
| FY2009 | Dec 31, 2009 | -$15.51M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.29M | -88.5% |
| Q1 FY2026 | Mar 31, 2026 | $358.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$411.58M | -354.6% |
| Q3 FY2025 | Sep 30, 2025 | -$103.39M | -565.8% |
| Q2 FY2025 | Jun 30, 2025 | $115.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$300.39M | -960.6% |
| Q4 FY2024 | Dec 31, 2024 | $161.68M | +556.6% |
| Q3 FY2024 | Sep 30, 2024 | $22.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$701.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $34.91M | – |
| Q4 FY2023 | Dec 31, 2023 | $24.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.84M | – |
| Q2 FY2023 | Jun 30, 2023 | -$133.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$138.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$106.83M | – |
| Q3 FY2022 | Sep 30, 2022 | -$131.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$211.13M | – |
| Q1 FY2022 | Mar 31, 2022 | -$86.88M | – |
| Q4 FY2021 | Dec 31, 2021 | -$105.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$34.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$167.57M | – |
| Q1 FY2021 | Mar 31, 2021 | -$151.87M | – |
| Q4 FY2020 | Dec 31, 2020 | -$170.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$137.07M | – |
| Q2 FY2020 | Jun 30, 2020 | -$138.35M | – |
| Q1 FY2020 | Mar 31, 2020 | -$118.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$230.22M | – |
| Q3 FY2019 | Sep 30, 2019 | -$123.59M | – |
| Q2 FY2019 | Jun 30, 2019 | -$275.37M | – |
| Q1 FY2019 | Mar 31, 2019 | -$76.39M | – |
| Q4 FY2018 | Dec 31, 2018 | -$139.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$70.10M | – |
| Q2 FY2018 | Jun 30, 2018 | -$103.43M | – |
| Q1 FY2018 | Mar 31, 2018 | -$30.74M | – |
| Q4 FY2017 | Dec 31, 2017 | -$23.15M | – |
| Q3 FY2017 | Sep 30, 2017 | -$45.91M | – |
| Q2 FY2017 | Jun 30, 2017 | -$63.34M | – |
| Q1 FY2017 | Mar 31, 2017 | -$39.25M | – |
| Q4 FY2016 | Dec 31, 2016 | -$88.40M | – |
| Q3 FY2016 | Sep 30, 2016 | -$56.53M | – |
See a number that looks wrong?